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Abstract: Colon cancer is the cancer of the epithelial cells lining the colon. This type of cancer occurs in many people 
that are either genetically predisposed or exposed to risk factors. Colorectal cancer is mainly divided into different stages 
according to invasiveness and metastatic ability of the tumor. Many mutations are acquired, leading to this malignancy. 
Treatment of colorectal cancer range from surgery in early stages to palliative care in most advanced stages. In this 
minireview, we summarize the latest findings on colorectal cancer. 
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 Colorectal cancer, commonly known as bowel cancer, 
occurs in the colon, rectum, or appendix. Genetic analysis 
shows that tumors in these three locations are genetically of 
the same cancer [1]. Colorectal cancer is the second most 
commonly diagnosed cancer in females, the third in males 
[2], and the forth around the world [3]. More than a million 
cases are yearly detected globally [4]. It is widespread in 
developed countries, where around 60% of the cases were 
diagnosed [5], most of which lead to death [6]. 
 There are several causes for the onset of colorectal 
cancers, which are nowadays better diagnosed and classified 
according to several criteria. Consistently, different 
treatments and prognostic measures are currently used to try 
and successfully cure this type of cancer [4]. 
CAUSES AND PREDISPOSITION 
 Colorectal cancer occurs in a wide range of people. Most 
of them were previously, and might still be exposed to 
numerous risk factors. The rest are either genetically 
predisposed, or associated with other bowel diseases. 
Risk Factors 
 It is estimated that more than 80% of patients with 
colorectal cancer were exposed to a number of risk factors, 
such as male gender, older age [4], high intake of red meat or 
fat, smoking and obesity [7]. The risk of alcohol increases at 
more than a drink per day [8]. Also, around 10% of these 
cases are related to insufficient activity [9]. 
Genetics 
 Around 18% of all cases are patients with a family 
history. Thus, they have a two to three-fold risk increase than 
other people. Furthermore, three main genetic diseases are  
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well associated with this type of cancer. The most common 
is known as the Lynch syndrome, or the hereditary 
nonpolyposis colorectal cancer (HNPCC) [4]. Familial 
adenomatous polyposis (FAP) [10] and Gardner syndrome 
[11] are both as well strongly associated with this type of 
cancer. 
Inflammatory Bowel Diseases 
 A third cause is the incidence of the Inflammatory Bowel 
Diseases, such as ulcerative colitis and Crohn’s disease [12]. 
The longer the onset of these diseases [13], and the worse the 
inflammation [14] will directly affect the risk of having 
colorectal cancer. However, only about 2% of this cancer is 
associated with the previously mentioned diseases [12]. 
PATHOGENESIS 
 Colorectal cancer originates from the epithelial lining, 
most often as a consequence of mutations in the Wnt 
signaling pathway. These mutations can be either acquired or 
inherited. They mostly occur in the intestinal gland stem 
cells [15]. 
Tumor Suppressor Genes 
 In all colorectal cancer, APC is the most commonly 
mutated gene. It produces the APC protein, which prevents 
the accumulation of the β-catenin protein by binding to and 
degrading it. In the absence of APC protein, β-catenin highly 
accumulates in the cytoplasm, translocates to the nucleus, 
and binds to DNA, thus activating the transcription of 
several genes. These genes are responsible for stem cell 
renewal and differentiation. However, when improperly 
expressed at elevated levels they cause cancer [16]. 
 Some colorectal cancers have high β-catenin levels due 
to mutations in its gene CTNNB1, and not in the APC gene. 
These mutations block the degradation of β-catenin. Other 
colorectal cancers have mutations in other APC analogues, 
such as NKD1, TCF7L2, AXIN1, or AXIN2. Another tumor 
suppressor, PTEN, normally inhibits the overexpressed 
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oncogene PI3K. However if PTEN is mutated, it becomes 
deactivated [16]. 
Apoptotic Proteins 
 Other than the defects mentioned above, additional 
mutations must take place for the cells to acquire more 
cancerous characteristics. One of these mutations occurs in 
the p53 protein, which is produced by the TP53 gene. This 
apoptotic protein monitors normal cell division. It kills the 
cells if they acquire any defect in the Wnt signaling pathway. 
Its mutation will change the tissue from a non-invasive 
adenoma into an invasive carcinoma [17]. In some cases, the 
gene encoding for BAX, another protective protein, is 
mutated, instead of the TP53 gene [16]. 
 Other apoptotic proteins are frequently mutated and 
deactivated in colorectal cancers. A major protein is the 
TGF-β, which in at least half of colorectal cancers has a 
deactivating mutation. In some cases, TGF-β is not the 
protein mutated, but its downstream protein SMAD (16). 
Another protein is the DCC protein, or Deleted in Colorectal 
Cancer. It acquires a deletion of its chromosomal segment 
[18]. 
Oncogenes 
 Normal genes that encode proteins, known as 
oncoproteins, responsible for the regulation of cell growth 
and differentiation are known as proto-oncogenes. They are 
mainly involved in signal transduction. When activated, 
increased expression or mutations will result in the 
transformation into oncogenes, which are tumor-inducing 
agents [19]. These are overexpressed in colorectal cancer, 
such as genes encoding the proteins PI3K, RAF, and RAS 
[20]. 
 Under normal conditions and in response to growth 
factors, these proteins will stimulate the cell to divide. 
Acquired mutations will lead to the over-activation of cell 
proliferation. In some cases, the chronological order of 
mutations is crucial for the progression of cancer. To 
illustrate, if at first a KRAS mutation occurred, this will lead 
to a self-limiting borderline lesion. On the other hand, if the 
KRAS mutation occurs after an APC mutation, it often leads 
to cancer [21]. 
 All the previously discussed mutations occur in one type 
of colorectal carcinomas, known as the hypermutated tumor 
type. These tumors have mutated forms of BRAF, TCF7L2, 
SLC9A9, MSH3, MSH6, TGFBR2, and ACVR2A. Genome-
scale analysis reveals that the non-hypermutated tumor type 
contains mutated ARIDIA, ATM, SOX9, and FAM123B. 
What is in common among the genes in both carcinomas is 
their involvement in the TGF-β and WNT signaling 
pathways. This, in turn, will result in the hyper activity of the 
central player in colorectal cancer, MYC [1].  
CLASSIFICATION OF COLORECTAL CANCER 
 The most widely used classification system is the TNM 
Staging System. It is considered the most descriptive and 
precise. T stands for the depth of the tumor, and to which 
level did it penetrate the colon wall. N refers to the 
involvement of lymph nodes. M stands for the degree of 
metastases that took place or whether the tumor has spread 
or not [22]. 
 Another less used system is the Duke’s system [23]. It 
was then modified and became the Modified Dukes Staging 
System. This system classifies the tumors under four main 
categories, i.e. A, B, C, and D. Modified Duke Stage A is the 
tumors that only reach the mucosal wall. B is the ones that 
penetrate through and out of the wall. C is the advancement 
of the tumor into the lymph nodes. D is when tumors are 
depicted in other organs, such as the liver, lung and bone 
[24]. 
SYMPTOMS AND DIAGNOSIS 
 Signs and symptoms of colorectal cancer greatly depend 
on its location and ability to metastasize. These include 
fever, loss of appetite, weight loss, constipation, and blood in 
stool. In people older than fifty, common symptoms are 
nausea, vomiting anaemia, and rectal bleeding [25]. It is 
important to note that the most evident symptoms are weight 
loss and rectal bleeding [26]. Without them all other 
symptoms can be indicative of several different 
gastrointestinal diseases [27]. 
 Colorectal cancers occurring on the right side of the 
colon, i.e. the ascending colon and cecum, usually cause 
severe fecal obstruction and anaemia. This is because these 
tumors tend to grow outward from a location of the bowel 
wall. However, left-sided tumors, i.e. tumors of the 
descending colon, cause constipation. These tumors are most 
likely circumferential [28]. 
 The first step towards diagnosis is to take tumor biopsy 
during wither colonoscopy or sigmoidoscopy. After 
confirming the presence of the cancer, imaging tests are 
performed of the patient’s chest, abdomen and pelvis, to 
determine the extent of the disease. These tests include CT 
scan, PET, and MRI. Based on these results, the physician 
can establish a clear idea of the stages of the cancer, 
depending on the TNM system of classification [4]. 
PATHOLOGY OF THE TUMOR 
 After biopsy or surgery, a pathology report explicitly 
determines the cell type and grade of the tumor. In 95% of 
the cases, the colon cancer type is adenocarcinoma [29]. It 
originates from the glandular epithelium, invading the wall 
and infiltrating all layers. Tumor cells have irregular 
structures and might secrete mucus. Depending on the 
predominant cellular pleomorphism, gland architecture, and 
secretion of mucus, adenocarcinoma is separated into three 
differentiation levels: poorly, moderately, and well 
differentiated. Other than adenocarcinoma, rare types of 
colorectal cancer include squamous cell carcinoma and 
lymphoma [30]. 
 Besides, the majority of colorectal cancer tumors are 
cyclooxygenase-2, or COX-2, positive. This enzyme is 
abundantly found in cancerous tissue of the colon. It aids in 
abnormal cell growth [31]. 
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TREATMENT AND PROGNOSIS 
 As any other type of cancer, the treatment of colorectal 
cancer depends on its advancement. At early stages, surgery 
is mostly curative. At later stages when the cancer is 
metastatic, physicians tend to treat their patients by trying to 
prolong their life and keep them comfortable [32]. 
Surgery 
 Patients with localized colorectal cancer undergo 
surgeries to extract the tumor. It is either done by laparotomy 
or laparoscopy, which is a minimally invasive procedure. If 
other tumors are metastasized to the lungs or liver, they are 
removed surgically [4]. 
Chemotherapy 
 In some cases, chemotherapy is used before surgery. This 
will help shrink the tumor before eradicating it. In other 
cases where the cancer has metastasized and entered the 
lymph nodes, chemotherapy is a must to help increase the 
life expectancy of the patient. Drugs may include oxaliplatin, 
irinotecan, leucovorin, UFT, capecitabine, or 5-fluorouracil. 
Monoclonal antibodies against molecular targets include 
cetuximab, panitumumab, or bevazicumab [33]. 
Understanding better the tumor biology and molecular 
pathways and mechanisms effectively led to the discovery of 
novel agents that specifically target molecular elements of 
cancer cells. This has helped improving the efficacy of drug-
based chemotherapy that is nowadays combined with 
targeted monoclonal antibodies. Research is being 
extensively done to try and use cell signaling pathways as 
targets for colorectal cancer treatment, even though these 
pathways highly intercorrelate and crosstalk [34]. 
Radiation 
 Combining chemotherapy and radiation might be helpful. 
But, in most cases, this is not used as curative technique, 
since the bowels are highly sensitive to radiation [35]. 
Palliative Care 
 At the stage when colorectal cancer becomes incurable, 
the best remedy is to improve the quality of life by allevia-
ting the symptoms and reducing the complications [36]. 
These procedures may include stent placement or bypassing 
part of the intestine, and pain medications. This will help 
reduce bleeding, intestinal obstruction, and abdominal pain 
[37]. 
 Survival rates are directly linked to the type of cancer and 
its detection. Late stage cancers have five times less survival 
rates that early stage ones [38]. To be on a safe side, follow-
up is highly mandatory. This will help diagnose any new 
tumors that develop later, but had not originated from the 
original tumor [39]. Physical examinations are recom-
mended, as well as blood tests and CT scans [40]. Close 
follow-up and intensive surveillance can reduce the five-year 
mortality rate of patients with colorectal cancer from 37% to 
30% [41, 42]. 
PREVENTION 
 The most important ways to prevent colorectal cancer are 
a healthy lifestyle, appropriate medication, and continuous 
screening. 
Life Style 
 Dietary recommendations include reducing the 
consumption of red meat and increasing the intake of fruits, 
vegetables, fibers and whole grains [43]. Physical activity 
also helps reducing the risk of colorectal cancer [44]. 
Medication 
 People at high risk of having colorectal cancer are 
advised to take aspirin and celecoxib. They both appear to 
decrease the risk factor. Nevertheless, these drugs are not 
recommended to those at average risk [45]. Vitamin D, 
especially its blood concentration, and Calcium intake are 
also associated with lower risks of colorectal cancer [46, 47]. 
Screening 
 Several screening methods are applied nowadays, and 
they proved to be helpful in reducing death by the early 
detection [48]. The three main tests are fecal occult blood 
testing of the stool, sigmoidoscopy, and colonoscopy [49]. 
The newest screening method is the M2-PK test to stool 
samples. The M2-PK enzyme biomarker is highly sensitive 
to colorectal cancer. It is able to detect bleeding and non-
bleeding types, which a fecal occult blood test cannot do 
[50]. 
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